Effects of a CB1 Antagonist/Inverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.

Prior treatment

• Participation in another clinical trial with pharmacological intervention the month prior to enrolment.
• History of severe psychiatric disorders, major depression or prior suicide attempts.
• Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers (inhibitors such as ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, or nefazodone, and inducers such as rifampicin, phenytoin, phenobarbital, carbamazepine, or St. John's Wort).

Other illness

• Known allergy to Rimonabant or any of the excipients used.
• Any other condition that, in the opinion of the investigator, makes the subject's participation in the study inadvisable, such as severe heart failure or uncontrolled diabetes.
• Patients with a history of ischemic or haemorrhagic stroke resulting in a residual mRS > 1, or with a pre-existing mRS > 1 due to other medical conditions.
• Fertile men or women who cannot guarantee the use of highly effective contraceptive methods, as defined by the European HMA-CTFG guidelines—i.e., those with a failure rate of less than 1 % per year when used consistently and correctly
• Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease.

Other

• High suicide risk assessed by C-SSRS.
• Body Mass Index > 40 kg/m2.
• Pregnancy or breastfeeding.
• Inability to attend hospital visits.

• Age between 18 and 75 years.
• Between 14 days and 3 months (14 – 90 days) since the stroke.
• Modified Rankin Scale (mRS) score between 2 and 4.
• Barthel Index (BI) score ≤ 70 at screening.
• Capacity to provide informed consent.